{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:29:44Z","timestamp":1790659784143,"version":"4.1.0"},"reference-count":30,"publisher":"Informa UK Limited","issue":"2","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmic Genetics"],"published-print":{"date-parts":[[2021,3,4]]},"DOI":"10.1080\/13816810.2020.1855663","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T23:34:23Z","timestamp":1607729663000},"page":"150-160","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Living with Stargardt disease: insights from patients and their parents"],"prefix":"10.1080","volume":"42","author":[{"given":"Aude","family":"Roborel de Climens","sequence":"first","affiliation":[{"name":"Clinical Outcomes Generation, Sanofi, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9atrice","family":"Tugaut","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes, ICON Plc, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Dias Barbosa","sequence":"additional","affiliation":[{"name":"Patient-Centered Outcomes, Mapi, an ICON Plc company, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Buggage","sequence":"additional","affiliation":[{"name":"Research and Development, Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brun-Strang","sequence":"additional","affiliation":[{"name":"Global Health Economics and Value Assessment Early Portfolio, Sanofi, Chilly-Mazarin, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"cit0001","unstructured":"Orphanet. Stargardt disease [Internet]. Paris, France: Ophanet; 2020 [accessed 2020 Feb 21]. https:\/\/www.orpha.net\/consor\/cgi-bin\/Disease_Search.php?lng=EN&data_id=158&Disease_Disease_Search_diseaseGroup=stargardt&Disease_Disease_Search_diseaseType=Pat&Disease(s)\/group%20of%20diseases=Stargardt-disease&title=Stargardt%20disease&search=Disease_Search_Simple."},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.08.032"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.13-13825"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.11.008"},{"key":"cit0005","unstructured":"Foundation Fighting for Blindness. Stargardt Disease [Internet]. Columbia, MD: FFB; 2019 [accessed 2020 May 14]. https:\/\/www.fightingblindness.org\/diseases\/stargardt-disease#living."},{"key":"cit0006","unstructured":"National Eye Institute. Facts About Stargardt Disease [Internet]. Bethesda, MD: NEI; 2015 [accessed 2020 May 14]. https:\/\/nei.nih.gov\/health\/stargardt\/star_facts."},{"key":"cit0007","volume-title":"Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology","author":"Brun-Strang C"},{"key":"cit0008","volume-title":"Paper presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology","author":"Buggage R"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2020.1737947"},{"key":"cit0010","unstructured":"Committee for Medicinal Products for Human Use. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. [Internet]. London, UK: European Medicines Agency; 2005 [accessed 2020 May 14]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf."},{"key":"cit0011","unstructured":"European Network for Health Technology Assessment. EUnetHTA JA2 WP8 Deliverable HTA Core Model Version 3.0 for the full assessment of Diagnostic Technologies, Medical and Surgical Interventions, Pharmaceuticals and Screening Technologies [Internet]. Diemen, The Netherlands: EUnetHTA; 2016 [accessed 2020 May 14]. https:\/\/www.eunethta.eu\/wp-content\/uploads\/2018\/03\/HTACoreModel3.0-1.pdf."},{"key":"cit0012","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. FDA Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient\u2019s Voice in Medical Product Development and Regulatory Decision Making [Internet]. Silver Spring, MD: FDA; 2018 [accessed 2020 May 14]. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical."},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-9071.2000.00312.x"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.171181"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.7.1050"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(00)00610-3"},{"issue":"3","key":"cit0017","first-page":"165","volume":"71","author":"Miedziak AI","year":"2000","journal-title":"Optometry"},{"key":"cit0018","first-page":"695","volume-title":"The sage handbook of qualitative research","author":"Fontana A","year":"2005","edition":"3"},{"key":"cit0019","unstructured":"Atlas.Ti. Version 7.0 [software]. Berlin, Germany: Scientific Software Development GmbHx; 2012."},{"key":"cit0020","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims [Internet]. Silver Spring, MD: FDA; 2009 [accessed 2020 May 14]. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf."},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1177\/009286150203600127"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-19936"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1177\/104973239500500201"},{"key":"cit0024","unstructured":"European Patients\u2019 Academy. Measuring Health-related quality of life (HRQoL) [Internet]. Brussels, Belgium: EUPATI; 2016 [accessed 2020 May 14]. https:\/\/www.eupati.eu\/health-technology-assessment\/measuring-health-related-quality-life-hrqol\/."},{"key":"cit0025","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Rare diseases: common issues in Drug Development Guidance for Industry. Draft guidance. [Internet]. Silver Spring, MD: FDA; 2019 [accessed 2020 May 14]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/rare-diseases-common-issues-drug-development-guidance-industry-0."},{"key":"cit0026","unstructured":"International Rare Diseases Research Consortium. Patient-centered outcome measures initiatives in the field of rare diseases [Internet]. Paris, France: IRDiRC; 2016 [accessed 2020 May 14]. http:\/\/www.irdirc.org\/wp-content\/uploads\/2017\/12\/PCOM_Post-Workshop_Report_Final.pdf."},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.004"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2020.1776337"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2018.1484931"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61376-3"}],"container-title":["Ophthalmic Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13816810.2020.1855663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T13:30:24Z","timestamp":1616506224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13816810.2020.1855663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3,4]]}},"alternative-id":["10.1080\/13816810.2020.1855663"],"URL":"https:\/\/doi.org\/10.1080\/13816810.2020.1855663","relation":{},"ISSN":["1381-6810","1744-5094"],"issn-type":[{"value":"1381-6810","type":"print"},{"value":"1744-5094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iopg20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iopg20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}